Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews published research on PQQ (pyrroloquinoline quinone) supplementation. It is informational only and is not medical advice. Not medical advice. Consult a qualified healthcare professional before starting any supplement, especially if you have an existing health condition or take prescription medications.

What PQQ buyers are actually trying to figure out

You have probably encountered PQQ marketed as “mitochondrial biogenesis support” — a claim that sounds meaningfully different from CoQ10’s electron transport angle but that you cannot fully evaluate without knowing whether the “creates new mitochondria” framing comes from a cell dish or from an actual human trial. You may also have seen that PQQ traces to Japanese research, and want to know whether that is a meaningful scientific origin story or a marketing overlay.

Both questions have concrete answers. The Japanese discovery claim is grounded in a real 2003 paper in Nature. The mitochondrial biogenesis mechanism is real but derives primarily from animal and cell culture research. The human RCT evidence remains limited in sample size and scope — that calibration is what honest coverage of PQQ requires before any purchasing decision.

The 2003 Nature letter and what Japanese researchers actually found

Pyrroloquinoline quinone was first isolated from bacteria in the 1970s. Its role as a bacterial redox cofactor was characterized through the 1980s. The claim that PQQ may matter for mammalian biology — not just bacterial metabolism — emerged from work by Japanese researchers published two decades later.

In April 2003, Takaaki Kasahara and Toshihiko Kato published a letter in Nature (volume 422, pages 832–835) proposing that PQQ functions as a new redox-cofactor vitamin for mammals (PubMed 12712201). The letter described PQQ’s presence in human breast milk and its distribution across plant foods — particularly fermented foods, green peppers, kiwi, and parsley — and presented evidence from rodent studies that PQQ deprivation impaired growth, reproductive outcome, and immune function. The authors argued these effects were consistent with a micronutrient role.

The Nature letter does not establish PQQ as an officially recognized human vitamin. That designation requires a more extensive and different standard of evidence than a rodent-deprivation study and a short human-exposure observation. What the 2003 paper accomplished was giving a peer-reviewed structural argument for mammalian PQQ essentiality and directing subsequent research toward its biological function in non-bacterial organisms. The Japanese research origin the supplement market references is this letter and the broader cellular work that followed it — neither is fabricated, but neither is the endpoint of the evidentiary chain.

PQQ versus CoQ10: where the axis separation actually is

The framing you will encounter for PQQ supplements — “builds new mitochondria” versus CoQ10’s “fuels existing mitochondria” — reflects a real functional distinction in the proposed mechanisms, though the human evidence for each is weighted very differently.

CoQ10 (ubiquinone / ubiquinol) operates within the mitochondrial respiratory chain as an electron carrier. It shuttles electrons between protein complexes in existing mitochondria, supporting ATP synthesis. Tissue CoQ10 levels decline with age; the clinical evidence includes a two-year randomized controlled trial (Q-SYMBIO, 2014) showing cardiovascular mortality signals in severe heart failure populations at 300 mg/day.

PQQ is proposed to act upstream: as a signaling stimulus for mitochondrial biogenesis — the process by which cells create new mitochondria rather than run existing ones more efficiently. The relevant pathway involves PGC-1α, a transcriptional coactivator that regulates mitochondrial number and oxidative capacity.

The cell biology evidence for this pathway comes from Chowanadisai et al. (2010), published in the Journal of Biological Chemistry (PubMed 19861415). Working at UC Davis, the researchers showed that PQQ treatment activated CREB phosphorylation and increased PGC-1α expression in HepG2 hepatocyte cells. Mitochondrial density markers increased in PQQ-supplemented animals. The paper is methodologically credible and the pathway is biologically coherent.

What the Chowanadisai paper does not show: whether oral PQQ supplementation in humans at achievable plasma concentrations replicates these cellular signaling changes at meaningful scale, or whether such changes translate to measurable clinical outcomes in the kinds of populations that purchase supplements. That is the gap between where the mechanism science sits and where the human trial record has reached.

What the human evidence actually shows

The human evidence on PQQ is limited in quantity and scale. The studies most often cited fall into two groups:

Metabolic marker data (Harris et al., 2013): The most directly relevant published human trial is Harris et al. (2013) in the Journal of Nutritional Biochemistry (PubMed 23773926). This crossover study enrolled 10 healthy subjects receiving 20 mg/day of PQQ versus a riboflavin-matched control for six weeks. The primary finding was a shift in urinary metabolites associated with TCA cycle function — tricarboxylic acid cycle intermediates that the authors interpreted as consistent with changes in mitochondrial-related metabolism. The study did not measure clinical endpoints: no energy assessments, no cognitive performance scores, no cardiovascular markers. A sample of 10 limits inference regardless of effect size.

Japanese cognition and fatigue studies: A series of small Japanese trials examined PQQ — alone or combined with CoQ10 — on cognitive test performance and fatigue self-report in older adults. These studies used 20 mg/day over eight to twelve weeks and observed associations with reduced fatigue ratings and attention test scores in some cohorts. They are heterogeneous in design, appear primarily in Japanese-language literature, and none reached sample sizes above approximately 40 participants. They point in a consistent direction but do not individually or collectively constitute confirmatory evidence.

Where this leaves the evidence level: For CoQ10, the human RCT database includes Q-SYMBIO (n=420, two-year follow-up, hard cardiovascular endpoints). PQQ’s equivalent does not exist. The animal and in vitro evidence for the mitochondrial biogenesis mechanism is more developed than most supplement categories, but human outcome data remains preliminary. The appropriate calibration is “may support” rather than “restores” or “increases mitochondrial mass.” Dose: published human studies have used 20 mg/day. Doses above 20 mg/day have limited safety or efficacy data in humans.

Side effects and interactions to know before starting

PQQ’s short-term tolerability within the 10–20 mg/day range appears adequate in published data. The Harris et al. (2013) crossover reported no significant adverse events at 20 mg/day. A manufacturer-sponsored dose-escalation report examined 60 mg/day and noted headache and fatigue at that higher dose; these were not reported at 20 mg/day.

Specific interaction considerations:

Anticoagulant therapy: No specific coagulation interaction has been identified for PQQ in published studies, distinguishing it from CoQ10’s documented reduction of warfarin effect. That absence of a known interaction is not equivalent to confirmed safety. If you take warfarin, antiplatelet agents, or other anticoagulant medications, disclose all supplements to your prescribing clinician — this applies regardless of PQQ-specific data.

Stimulant sensitivity: Some users report mild alertness increases or difficulty sleeping when PQQ is taken in the afternoon or evening. This pattern is anecdotal and inconsistently described in clinical trial reports, but it appears frequently enough in consumer experience to note as a dosing-timing consideration — take PQQ in the morning if you are caffeine-sensitive or sleep-sensitive.

Pregnancy and lactation: PQQ is present in human breast milk at detectable concentrations — its natural occurrence is documented in the Kasahara and Kato 2003 letter. Supplemental PQQ during pregnancy or breastfeeding has not been studied for safety or appropriate dose. Presence in breast milk as a natural trace compound does not establish safety of gram-range supplemental doses during these periods.

PQQ has not been evaluated in populations with severe hepatic or renal impairment.

Three PQQ products currently available on Amazon

The description for this article specifically identified NOW Foods, Jarrow Formulas, and Life Extension as carrying PQQ at the 20 mg dose that appears in published human research:

NOW Foods PQQ 20 mg: NOW Foods is a US supplement manufacturer with GMP certification and a track record of single-ingredient formulations at research-relevant doses. Their PQQ product is a single-ingredient capsule at 20 mg. Search on Amazon.

Jarrow Formulas PQQ: Jarrow formulates based on published ingredient research and labels the PQQ product as PQQ Biosynthesis Factor, reflecting the mitochondrial biogenesis mechanism angle. Typically formulated at 20 mg per capsule. Available on Amazon.

Life Extension PQQ Caps: Life Extension publishes third-party testing documentation and has a long record in the clinical evidence-oriented supplement segment. Their PQQ caps are available in 10 mg and 20 mg formulations. Available on Amazon.

Across all three, confirm that the supplement facts panel lists PQQ or pyrroloquinoline quinone disodium salt — the form used in published human studies — rather than an ambiguous “PQQ complex” without further ingredient specification.

Who should talk to a clinician before starting

• Anyone taking prescription medications for metabolic, cardiovascular, or neurological conditions: PQQ has not been evaluated for drug interactions in most prescription medication contexts. Disclose it to your prescribing clinician the same way you would disclose any new supplement.
• Pregnant or breastfeeding individuals: No adequate safety study of supplemental PQQ exists in these populations. Natural presence in breast milk as a trace compound is a different exposure than supplemental 20 mg/day.
• Anyone managing an established diagnosis with mitochondrial or energy metabolism components: PQQ supplementation should be disclosed to the treating clinician. The human evidence, at this stage, does not position PQQ as a clinical intervention equivalent to established pharmacological management — it is a research-stage candidate with supportive but preliminary human data.

Questions worth raising before starting:

• Given that the human evidence is limited to small metabolic marker studies and Japanese cognition trials with sample sizes under 40, what is my personal risk-benefit consideration relative to other interventions with larger human RCT bases?
• Is there a reason to add PQQ separately from, or in addition to, CoQ10 for my specific situation?
• Are there any medications in my current regimen where the absence of a known interaction should still be disclosed and monitored?

The honest position on PQQ: the Japanese research origin is not marketing invention — Kasahara and Kato’s 2003 Nature letter and the Chowanadisai cell biology work represent real science from a legitimate discovery lineage. The mitochondrial biogenesis mechanism is biologically plausible and supported by in vitro and animal data. The gap is in human trials: what exists is small, heterogeneous, and focused on biomarker surrogates and self-reported outcomes rather than clinical endpoints. Supplementing PQQ at 20 mg/day appears to be tolerated in the short-term data available. Expectations should be calibrated to that evidence base — neither dismissed as implausible nor treated as established clinical benefit.

---

For related reading on Japanese-origin mitochondrial supplement research: Kaneka CoQ10: The Japanese Manufacturer Behind Most Ubiquinol Supplements, and What the Cardiac Evidence Shows, Ergothioneine from Japanese Mushrooms: The Cytoprotective Antioxidant and Longevity Research.